Compare Celestica Inc (CLS) vs GSK plc (GSK) Price & Performance

CLS trades at $336.97, up 7.11% on the day, with a bearish technical signal from moving averages but strong fundamental performance. The company reported three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.54 exceeding the $2.29 estimate. Revenue for 2025 was $12.39 billion, with a net income margin of 7.16% and robust ROE of 52.69%. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, alongside new contracts with key tech partners.

The outlook is supported by accelerating AI-driven demand and raised guidance, but near-term dilution from the equity raise poses a risk. Analyst consensus is strongly bullish with a $466.50 price target, though the stock's premium valuation requires careful monitoring of execution against growth expectations.

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.